

Ana Carneiro

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3266311/ana-carneiro-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,291
citations

14
h-index

33
g-index

33
ext. papers

1,892
ext. citations

6.1
avg, IF

4.17
L-index

#	Paper	IF	Citations
30	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020 , 577, 561-565	56.4	542
29	Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 581-592	7.4	141
28	Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015 , 6, 12297-309	3.3	102
27	NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics. <i>Molecular Oncology</i> , 2017 , 11, 438-451	7.9	73
26	Multiregion Whole-Exome Sequencing Uncovers the Genetic Evolution and Mutational Heterogeneity of Early-Stage Metastatic Melanoma. <i>Cancer Research</i> , 2016 , 76, 4765-74	10.1	70
25	Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. <i>BMC Cancer</i> , 2008 , 8, 98	4.8	63
24	A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. <i>Cancer</i> , 2011 , 117, 1279-87	6.4	42
23	The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. <i>Cell Reports</i> , 2019 , 27, 3573-3586.e7	10.6	36
22	Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?. <i>Laboratory Investigation</i> , 2009 , 89, 668-75	5.9	36
21	Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. <i>BMC Cancer</i> , 2019 , 19, 415	4.8	33
20	Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. <i>Journal of Clinical Pathology</i> , 2011 , 64, 689-94	3.9	19
19	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. <i>Molecular Oncology</i> , 2020 , 14, 933-950	7.9	16
18	The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma. <i>Nature Communications</i> , 2021 , 12, 5155	17.4	16
17	Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9524-9524	2.2	14
16	Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 9504-9504	2.2	13
15	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. <i>Cancers</i> , 2020 , 12,	6.6	12
14	Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome. <i>Familial Cancer</i> , 2014 , 13, 537-45	3	11

13	A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2839-2845	3.1	8
12	Human G-MDSCs are neutrophils at distinct maturation stages promoting tumor growth in breast cancer. <i>Life Science Alliance</i> , 2020 , 3,	5.8	8
11	Rescue Effect Inherited in Colony Formation Assays Affects Radiation Response. <i>Radiation Research</i> , 2018 , 189, 44-52	3.1	7
10	Discovery-based protein expression profiling identifies distinct subgroups and pathways in leiomyosarcomas. <i>Molecular Cancer Research</i> , 2014 , 12, 1729-39	6.6	3
9	A first-in-human phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3061-3061	2.2	3
8	Genetic profiling differentiates second primary tumors from metastases in adult metachronous soft tissue sarcoma. <i>Sarcoma</i> , 2008 , 2008, 431019	3.1	2
7	Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9526-9526	2.2	2
6	Surgery of metastatic melanoma after systemic therapy - the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta Oncologica</i> , 2021 , 60, 52-55	3.2	2
5	Prognostic value of proliferation in pleomorphic soft tissue sarcomas: a new look at an old measure. <i>Human Pathology</i> , 2012 , 43, 2247-54	3.7	1
4	A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2646-2646	2.2	1
3	17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcγRIIb, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , 2020 , 136, 36-37	2.2	
2	Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to FcγRIIb, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , 2021 , 138, 1354-1354	2.2	
1	A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS2653-TPS2653	2.2	